Full history for every metric is available with a Kvantra account
TheraVet S.A. (ALVET.PA)
Key financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | - | 1 | 1 | 2 | 2 | 1 | 1 |
| Operating profit | €m | -2 | -2 | |||||
| Net profit | €m | - | -0 | -0 | -1 | -2 | -2 | -2 |
| EPS reported | € | -0.49 | -0.46 | |||||
| Operating cashflow per share | € | -0.38 | -0.38 | |||||
| Capex per share | € | 0.31 | 0.31 | |||||
| FCF per share | € | -0.52 | -0.52 | |||||
| Free cash flow | €m | -2 | -1 | |||||
| Net debt | €m | 0 | 1 | |||||
| Book value equity | €m | 6 | 5 | |||||
| Book value per share | € | 1.88 | 1.64 | |||||
| Number of shares | m | 3.23 | 3.22 | |||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.77 | 1.90 | |||||
| P/S LTM | x | 4.34 | 10.91 | |||||
| P/FCF LTM | x | -2.78 | -8.33 | |||||
| EV/EBITDA LTM | x | -8.93 | -7.81 | |||||
| EV/Sales LTM | x | 4.35 | 11.72 | |||||
| Earnings Yield LTM | % | -33.59% | -593.90% | |||||
| FCF Yield | % | -35.95% | -12.00% | |||||
| Quality | ||||||||
| ROE | % | -25.97% | -23.15% | |||||
| ROIC | % | -29.32% | -29.32% | |||||
| Operating margin | % | -201.76% | -201.76% | |||||
| Gross margin | % | -49.24% | -49.24% | |||||
| FCF/Sales | % | -155.95% | -155.95% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -32.70% | +761.86% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.45 | -0.83 | |||||
| Net Debt/EBITDA | x | -0.02 | -0.02 | |||||
| EBIT/Net interest | x | -89.65 | -89.65 | |||||
| Net debt/market cap | % | 0.27% | 7.39% | |||||
| Net debt/Equity | x | 0.00 | 0.14 | |||||
| Gross debt/equity | x | 0.19 | 0.28 | |||||
Company overview
TheraVet S.A. operates as a veterinary biotechnology firm, delivering specialized osteoarticular therapies for animals across Belgium, France, Switzerland, the United Kingdom, and the United States. The company's primary focus is on providing solutions for osteoarthritis, ligament and tendon damage, and bone surgery requirements in felines, canines, and equines. Its product lineup includes BIOCERA-VET, formulated to enhance bone integration and remodeling, and VISCO-VET. The latter is an injectable, hyaluronic acid-based gel that facilitates regeneration, exhibits anti-inflammatory characteristics, boosts the effectiveness of active compounds, and promotes cellular colonization essential for tissue repair. Founded in 2017, TheraVet S.A. has its corporate base situated in Jumet, Belgium.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
TheraVet S.A. (ALVET.PA)
TheraVet S.A. operates as a veterinary biotechnology firm, delivering specialized osteoarticular therapies for animals across Belgium, France, Switzerland, the United Kingdom, and the United States. The company's primary focus is on providing solutions for osteoarthritis, ligament and tendon damage, and bone surgery requirements in felines, canines, and equines. Its product lineup includes BIOCERA-VET, formulated to enhance bone integration and remodeling, and VISCO-VET. The latter is an injectable, hyaluronic acid-based gel that facilitates regeneration, exhibits anti-inflammatory characteristics, boosts the effectiveness of active compounds, and promotes cellular colonization essential for tissue repair. Founded in 2017, TheraVet S.A. has its corporate base situated in Jumet, Belgium.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free